Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

MLA

Lugui Qiu, et al. Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial. Apr. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22490801.

APA

Lugui Qiu, Zusheng Xu, Hanying Bao, Shuhua Yi, Zengjun Li, Lihong Liu, Weiliang Zhu, Xuekui Gu, Weixin Wu, Fei Li, Jie Jin, Weijun Fu, Zhihui Zhang, Zhen Cai, Hong Cen, Zhifeng Li, Yu Yang, Hui Zhou, Keshu Zhou, … Tingyu Wang. (2023). Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial. https://doi.org/10.1158/1078-0432.22490801

Chicago

Lugui Qiu, Zusheng Xu, Hanying Bao, Shuhua Yi, Zengjun Li, Lihong Liu, Weiliang Zhu, et al. 2023. “Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial,” April. doi:10.1158/1078-0432.22490801.